|
|
|
Synonyms
|
Why do we do this test?
To monitor and assess the response to treatment in cancer ovary and endometrium. Used in the long term follow up after completion of therapy to detect recurrences.
CA 125 is a protein that is present on the surface of most, but not all, ovarian cancer cells. Therefore not all women with ovarian cancers will have elevated CA125, making CA 125 not a very good marker for screening. It is also elevated in various other cancers as well as some non-cancerous conditions such as endometriosis, pericarditis (fluid around heart), pleural effusions (fluid around lungs) cirrhosis ans hepatitis.
|
|
Specimen Type
Serum, Plasma (EDTA), Plasma (Li Heparin)
|
|
|
Instructions for specimen
collection & Patient preparation
|
Specimen transportation &
Processing
Separate serum as soon as possible. Transport separated serum/plasma in ice
(2-8C)
|
|
Specimen storage & stability
For prolonged storage keep frozen at -20C. If analysis with-in 5 days stable at 0C.
|
|
Specimen storage duration
|
Reference Intervals & Target
Values
For non-pregnant <35.0 U/mL
|
|
Critical Limits
|
|
Possible Pre-analytical Errors
|
Possible Analytical Errors
Insufficient serum/plasma volume, Air bubbles, Fibrin clots
|
|
Available Government Laboratories
Apeksha Hospital, Medical Research Institute, National Hospital Kandy, Teaching Hospital Jaffna, Karapitiya Teaching Hospital
|
|
|
Recommended turnaround time
|
|
Test Method
|
Documentation
|
|
References
1. Sturgeon CM, Duffy MJ, Stenman UH, et al; National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumour markers in testicular, prostate, colorectal, breast and ovarian cancers. Clin Chem 2008 Dec;54(12):e11-79
2. Daniel W.Chan, Stewart Sell; Tumour Markers. Burtis CA, Ashwood ER. Tietz Text Book of Clinical Chemistry,3rd edition, USA, Elsevier Saunders 1999, 722-749
|
|
|
Last Updated : 2020-09-23 04:52:38 |
